Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.
China
Crowdsourcing
Hepatitis C virus (HCV)
Linkage-to-care
Primary care
Testing
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
02 Jul 2020
02 Jul 2020
Historique:
received:
28
02
2020
accepted:
18
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
29
10
2020
Statut:
epublish
Résumé
Hepatitis C virus (HCV) is a growing public health problem with a large disease burden worldwide. In China many people living with HCV are unaware of their hepatitis status and not connected to care and treatment. Crowdsourcing is a technique that invites the public to create health promotion materials and has been found to increase HIV testing uptake, including in China. This trial aims to evaluate crowdsourcing as a strategy to improve HCV awareness, testing and linkage-to-care in China. A randomized controlled, two-armed trial (RCT) is being conducted in Shenzhen with 1006 participants recruited from primary care sectors of The University of Hong Kong-Shenzhen Hospital. Eligible participants are ≥30 years old; a resident in Shenzhen for at least one month after recruitment; no screening for HCV within the past 12 months and not known to have chronic HCV; and, having a WeChat social media account. Allocation is 1:1. Both groups will be administered a baseline and a follow-up survey (4-week post-enrollment). The intervention group will receive crowdsourcing materials to promote HCV testing once a week for two weeks and feedback will be collected thereafter, while the control group will receive no promotional materials. Feedback collected will be judged by a panel and selected to be implemented to improve the intervention continuously. Those identified positive for HCV antibodies will be referred to gastroenterologists for confirmation and treatment. The primary outcome will be confirmed HCV testing uptake, and secondary outcomes include HCV confirmatory testing and initiation of HCV treatment with follow-ups with specialist providers. Data will be collected on Survey Star This will be the first study to evaluate the impact of crowdsourcing to improve viral hepatitis testing and linkage-to-care in the health facilities. This RCT will contribute to the existing literature on interventions to improve viral hepatitis testing in primary care setting, and inform future strategies to improve HCV care training for primary care providers in China. Chinese Clinical Trial Registry. ChiCTR1900025771. Registered September 7th, 2019, http://www.chictr.org.cn/showprojen.aspx?proj=42788.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) is a growing public health problem with a large disease burden worldwide. In China many people living with HCV are unaware of their hepatitis status and not connected to care and treatment. Crowdsourcing is a technique that invites the public to create health promotion materials and has been found to increase HIV testing uptake, including in China. This trial aims to evaluate crowdsourcing as a strategy to improve HCV awareness, testing and linkage-to-care in China.
METHODS
METHODS
A randomized controlled, two-armed trial (RCT) is being conducted in Shenzhen with 1006 participants recruited from primary care sectors of The University of Hong Kong-Shenzhen Hospital. Eligible participants are ≥30 years old; a resident in Shenzhen for at least one month after recruitment; no screening for HCV within the past 12 months and not known to have chronic HCV; and, having a WeChat social media account. Allocation is 1:1. Both groups will be administered a baseline and a follow-up survey (4-week post-enrollment). The intervention group will receive crowdsourcing materials to promote HCV testing once a week for two weeks and feedback will be collected thereafter, while the control group will receive no promotional materials. Feedback collected will be judged by a panel and selected to be implemented to improve the intervention continuously. Those identified positive for HCV antibodies will be referred to gastroenterologists for confirmation and treatment. The primary outcome will be confirmed HCV testing uptake, and secondary outcomes include HCV confirmatory testing and initiation of HCV treatment with follow-ups with specialist providers. Data will be collected on Survey Star
DISCUSSION
CONCLUSIONS
This will be the first study to evaluate the impact of crowdsourcing to improve viral hepatitis testing and linkage-to-care in the health facilities. This RCT will contribute to the existing literature on interventions to improve viral hepatitis testing in primary care setting, and inform future strategies to improve HCV care training for primary care providers in China.
TRIAL REGISTRATION
BACKGROUND
Chinese Clinical Trial Registry. ChiCTR1900025771. Registered September 7th, 2019, http://www.chictr.org.cn/showprojen.aspx?proj=42788.
Identifiants
pubmed: 32615951
doi: 10.1186/s12889-020-09152-z
pii: 10.1186/s12889-020-09152-z
pmc: PMC7330974
doi:
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1048Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Gilead Sciences
ID : IN-CN-987-5376
Références
Clin Infect Dis. 2016 Jun 1;62(11):1436-1442
pubmed: 27129465
Nat Med. 2013 Jul;19(7):850-8
pubmed: 23836235
PLoS Med. 2018 Aug 28;15(8):e1002645
pubmed: 30153265
Int J Infect Dis. 2019 Mar;80:16-27
pubmed: 30529371
Expert Rev Anti Infect Ther. 2019 Oct;17(10):763-773
pubmed: 31578079
BMC Infect Dis. 2018 Sep 29;18(1):489
pubmed: 30268114
J Viral Hepat. 2015 Mar;22(3):238-44
pubmed: 25131856
J Viral Hepat. 2018 Dec;25(12):1543-1554
pubmed: 29851287
J Med Internet Res. 2017 Jul 19;19(7):e251
pubmed: 28724510
Lancet Infect Dis. 2016 Dec;16(12):1409-1422
pubmed: 27615026
Fam Pract. 2018 Dec 12;35(6):731-737
pubmed: 29741661
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
BMJ Open. 2016 Oct 3;6(10):e010755
pubmed: 27697868
Virol J. 2019 Apr 16;16(1):47
pubmed: 30992019
Hepatol Int. 2015 Jul;9(3):378-90
pubmed: 26071238
Clin Microbiol Infect. 2011 Feb;17(2):107-15
pubmed: 21091831
BMC Infect Dis. 2014 Sep 08;14:490
pubmed: 25200651
Clin Gastroenterol Hepatol. 2018 May;16(5):778-780
pubmed: 28988876
Gastroenterology. 2014 May;146(5):1145-50.e1-4
pubmed: 24662488